A recent survey indicates that approximately three million Canadian adults are presently using GLP-1 medications such as Ozempic or Mounjaro, and a significant number desire to use them but are deterred by costs. The research by Leger Healthcare reveals that over half of respondents who are on these drugs reported a decrease in appetite, and 40 percent noted reduced food cravings. Consequently, their spending habits are shifting, with around 30 percent dining out less frequently or opting for takeout less often.
Moreover, the survey highlights that one-third of GLP-1 users have increased their purchases of fresh produce, vegetables, and protein-rich foods. Weight loss emerges as the primary motivation for taking or contemplating the use of GLP-1 medications, followed by managing diabetes. Notably, 22 percent expressed interest in GLP-1s for heart health reasons, with men more inclined toward this than women.
Approximately 8 percent of survey participants confirmed using prescription GLP-1 medications, which Leger Healthcare extrapolated to about three million Canadian adults based on 2025 population data. Similarly, 6 percent expressed interest in these medications but had not yet started, equating to over two million Canadian adults.
The survey indicated higher GLP-1 utilization in the United States, with 11 percent of Americans surveyed reporting medication use. Americans also displayed greater interest in these drugs compared to Canadians, with 12 percent expressing curiosity. For many Canadians considering GLP-1 use, factors like insurance coverage and affordable generic options play a significant role in their decision-making.
Melicent Lavers-Sailly, vice president of research at Leger Healthcare, emphasized that GLP-1 medications have transitioned from a niche topic to a mainstream consumer and healthcare concern. These drugs are influencing not just prescriptions but also consumer behavior, as evident in changes like reduced restaurant visits and altered food choices among users.
Additionally, the survey revealed that GLP-1 users are diversifying their spending beyond groceries, with increased investments in clothing, personal care items, beauty services, and fitness activities. While cost and insurance coverage remain obstacles for some potential users, concerns about side effects also influence decisions, with 36 percent stating they would consider GLP-1s if side-effect risks were lower.
Gastrointestinal side effects like nausea, vomiting, constipation, and diarrhea are commonly reported, but severe complications such as gall bladder inflammation and pancreatitis are rare. Despite some concerns, most side effects are minor and manageable, according to medical professionals.